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Radiation recall pneumonitisa b s t r a c t
Background and purpose: Radiation recall pneumonitis (RRP) is a delayed radiation-induced lung toxicity
triggered by systemic agents, typically anticancer drugs. Immune checkpoint inhibitors (ICIs) have
recently been identified as potential causal agents of RRP but its real incidence and potential risk factors
remain unknown.
Materials and methods: Medical records and CTs of patients treated with programmed death 1 (PD-1) or
programmed death ligand 1 (PD-L1) inhibitors for advanced lung cancer between 2014 and 2019 at our
tertiary center, and who had a previous history of lung irradiation were retrospectively analyzed. We
identified RRP as lung CT modifications occurring in the irradiation field >6 months after conventionally
fractionated radiotherapy completion and >1 year after stereotactic body radiation therapy. Clinical and
dosimetric data were analyzed to identify potential risk factors for RRP.
Results: Among 348 patients treated with ICIs, data from 80 eligible patients were analyzed (median age,
69 years [interquartile range, 11]; 45 men). Fifteen patients (18.8%) presented with RRP. Median time
between end of radiotherapy and RRP was 450 days (range, 231–1859). No risk factor was significantly
associated with RRP. ICI-related pneumonitis was associated with RRP in 33.3% of cases (p = 0.0021),
developing either concomitantly or after RRP. Incidence of grade  3 pneumonitis in the RRP population
was 13.3 %.
Conclusion: We demonstrated a high incidence of RRP (18.8%) in our population of previously irradiated
patients treated with ICIs for lung cancer. We identified no risk factors for RRP, but an association was
noted between RRP and ICI-related pneumonitis.
 2021 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 157 (2021) 47–55Radiation recall describes an unpredictable inflammatory reac-
tion within previously irradiated tissue. It is triggered by pharma-
cological agents, typically anticancer drugs.
This phenomenon was first described in 1959 by D’Angio et al.
who reported the reactivation of latent radiation dermatitis after
actinomycin D therapy [1]. It has since been observed in many
other tissues such as muscles, bowel, central nervous system and
lungs [2–5]. This poorly understood reaction differs from the clas-
sical radiation-induced toxicity in the sense that it occurs typically
tardily, sometimes several years after irradiation [6]. Radiation
recall pneumonitis (RRP), has been subject to particular concern
because lesions visible on lung CT can be extensive, sometimesassociated with severe symptoms leading to treatment
discontinuation.
Anticancer molecules most commonly involved with RRP are
classical chemotherapeutic agents, such as taxanes, gemcitabine,
and targeted therapies such as tyrosine kinase inhibitors [5,7].
More recently, several cases of radiation recall pneumonitis associ-
ated with immune checkpoint inhibitors (ICIs) have also been
described [6,8,9]. In the last decade, ICIs have demonstrated
unprecedented efficacy in the treatment of many advanced malig-
nancies such as lung cancer [10]. However, as ICIs act by harness-
ing the immune system in order to limit tumor proliferation, they
have been associated with a panel of specific inflammatory adverse
events called immune-related adverse events, among which pneu-
monitis [11,12]. With the increasing use of ICIs in advanced lung
cancer, we can expect that previously irradiated patients will be
more exposed to radiation recall phenomenon, especially to the
lungs due to the combined toxicity. Occurrence of such abnormal-
ities on lung CT in a patient during follow-up under ICIs is always
challenging. Therefore, a deeper understanding of RRP and its early
Radiation recall pneumonitis and immune checkpoint inhibitorsrecognition on imaging are both crucial. Yet, little is known about
incidence and risk factors for RRP in the setting of immunotherapy
[13].
We therefore conducted a retrospective study to assess the inci-
dence, the clinical and radiological characteristics and the potential
risk factors of RRP in a population of patients with lung cancer
treated with programmed death 1 (PD-1) or anti-programmed
death-ligand 1 (PD-L1) inhibitors.Materials and methods
Patients
We retrospectively reviewed the medical, radiological and radi-
ation therapy records of all patients treated with PD-1/PD-L1 inhi-
bitors for advanced lung cancer between 2015 and 2019 at our
institution. Patients were included in our study if they had received
thoracic irradiation (either to the lung, the mediastinum, the tho-
racic wall or the breast), of any type, with a minimum total dose
of 15 Gy (pneumonitis is not expected to occur with smaller doses)
[14,15]. Radiotherapy had to be terminated before initiation of





Women, n (%) 30 (46)
Men, n (%) 35 (54)
Median age, y (IQR) 67 (11)
Smoking history, n (%) 62 (95)













Prior chemotherapy, n (%) 49 (75)
Concurrent CT-RT, n (%) 26 (40)
Combined chemotherapy, n (%) 3 (5)














Median MLD, Gy (IQR) 10.2 (9.7)
Median V20, % (IQR) 16.1 (16.8)
Median time between end of RT and ICI initiation, d (IQR) 388 (524)
ICI-related pneumonitis, n (%) 2 (3)
Median PFS, m (IQR) 235 (347)
Median OS, m (IQR) 384 (369)
1 Other includes large cell carcinoma, small cell carcinoma and carcinoma not othe
inhibitor; CT-RT, chemoradiotherapy; SBRT, stereotactic body radiation therapy; MLD,
survival; OS, overall survival.
48received concurrent ICIs and radiotherapy, or ICIs before radiother-
apy, were excluded. Patients who had the irradiated lung area sur-
gically removed before ICI initiation were excluded. Patients who
received a maintenance treatment with durvalumab following tho-
racic chemoradiation were not included because they represent a
very specific population with a high risk of lung toxicity due to
treatments cumulative effects.
The following demographic and clinical data, summarized in
Table 1, were collected: age, sex, smoking history, presence of lung
emphysema or interstitial lung disease assessed by imaging prior
to ICI initiation, overall survival (OS), progression-free survival
(PFS), tumor histology, tumoral PD-L1 expression, ICI molecule,
prior chemotherapy and development of an ICI-related
pneumonitis.
PFS was defined as the time from the first dose of ICI to disease
progression according to immune Response Evaluation Criteria in
Solid Tumors (iRECIST), or death from any cause.
OS was defined as the time from the first dose of ICI to the date
of death from any cause.
The diagnosis of ICI-related pneumonitis was determined in the
multidisciplinary tumor board, including at least a pulmonologist,






5 (33) 35 (44)
10 (67) 45 (56)
70 (10) 69 (11) 0.33
14 (93) 76 (95) 0.57
0.55
4 (27) 24 (30)
6 (40) 23 (29)
2 (13) 20 (25)
3 (20) 13 (16)
0.27
6 (40) 30 (38)
6 (40) 37 (46)
3 (20) 13 (16)
0.58
10 (67) 53 (66)
2 (13) 16 (20)
3 (20) 11 (14)
11 (73) 60 (75) 0.55
8 (53) 34 (43) 0.89
1 (7) 4 (5) 0.57
0.10
0 (0) 5 (6)
12 (80) 61 (76)
3 (20) 14 (18)
0.58
60 (16.5) 66 (12)
60 (5) 60 (10)
/ 17 (0)
0.86
2 (0.5) 2 (0.1)
12 (5) 16 (10)
/ 8.5 (0)
11 (9.2) 10.5 (9.3) 0.84
19.6 (17.4) 17.7 (16.8) 0.66
320 (499) 368.5 (529) 0.89
5 (33) 7 (9) 0.002
324 (291) 262 (340) 0.99
376 (535) 384 (392) 0.84
rwise specified (NOS). RRP, radiation recall pneumonitis; ICI, immune checkpoint
mean lung dose; RT, radiotherapy; IQR, interquartile range; PFS, progression free
François Cousin, C. Desir, S. Ben Mustapha et al. Radiotherapy and Oncology 157 (2021) 47–55diffuse lung abnormalities on CT, after exclusion of other
alternative etiologies such as infection or tumor progression. The
following radiation parameters were collected: type of radiother-
apy (palliative, conventionally fractionated or stereotactic body
radiation therapy (SBRT)), region targeted, total dose, dose per
fraction, mean lung dose, V20 (volume of lung receiving 20 Gy).
This study received approval from our institutional review
board, and the need for informed consent was waived based on
its retrospective design.CT analysis
Radiological follow-up by lung CT, with or without contrast
media, of at least 6 months after conventionally fractionated radio-
therapy and 1 year after SBRT was needed for inclusion. Patients
were also required to have had at least one lung CT prior to ICI ini-
tiation (baseline CT) and at least one lung CT carried out after ICI
initiation.
All CTs (baseline CTs and follow up CTs under ICIs) were
reviewed in consensus by two board-certified radiologists who
were unaware of the initial report (F.C. and C.D, with respectively
5 and 1 years of experience in thoracic imaging).
RRP was defined, in opposition to ICI-related pneumonitis, as
the appearance of typical radiological changes of radiation pneu-
monitis on CT (homogeneous or patchy areas of ground glass opac-
ity or consolidation, evolving progressively to retractile and fibrotic
changes over time) developing within the radiation field later than
6 months after conventionally fractionated radiotherapy and later
than 1 year after SBRT [16,17]. All new lung modifications were
included, regardless of the presence of preexisting radiation-
induced lung fibrosis. Pulmonary infection was ruled out by bron-
choscopy microbiology and/or clinical course. Tumor recurrence
was distinguished from RRP based on radiological criteria and/or
long term clinical and radiological follow up. Occurrence time of
RRP was defined as the time between radiotherapy completion
date and the date of the CT on which first lung modifications were
seen. The severity of the pneumonitis was evaluated using the
Common Terminology Criteria for Adverse Events v 5.0 grades.
The presence of respiratory symptoms related to RRP was also
assessed.
The following radiological characteristics concerning RRP were
assessed on CT: presence of prior radiation-induced lung fibrosis
(consolidation with volume-loss, parenchymal distortion and trac-
tion bronchiectasis), presence of ground glass opacities and/or con-
solidations, distribution of lung changes within the irradiation field
(diffuse or patchy). We retrospectively reviewed the initial radio-
logical reports of the CTs of patients with RRP and the diagnoses
made at that time were analyzed.Fig. 1. Patients disposition. ICI, immune checkpoint inhibitor; RRP, radiation recall
pneumonitis.Statistics
Results are expressed as numbers and frequencies for qualita-
tive parameters and as mean and standard deviation, median and
interquartile range and range for quantitative parameters. The nor-
mality of the quantitative parameters was investigated using the
mean-median comparison, the histogram and Quantile-Quantile
plot and the Shapiro–Wilk test. Comparison between the two
groups (patients with or without RRP) was assessed using a Chi-
squared test (or Fisher’s exact test) for qualitative risk factors
and the Mann-Whitney test for quantitative risk factors. Compar-
ison of RRP grade between groups was assessed using a Kruskal–
Wallis test. Correlations between RRP grade and quantitative risk
factors were calculated and tested with a Spearman correlation
test.49Statistical significance was set at p < 0.05. All statistical analyses
were performed using SAS v 9.4 software (SAS Institute, Cary, NC).Results
A total of 348 patients with advanced lung cancer treated with
PD-1/PD-L1 inhibitors were identified, of whom 112 had prior lung
irradiation. Thirty-two patients were excluded due to either insuf-
ficient CT follow-up, irradiation dose to the lung less than 15 Gy or
surgical excision of the irradiated lobe (Fig. 1). A total of 80
patients were included in our statistical analysis (median age,
69 years [interquartile range, 11]; 45 men). Demographic charac-
teristics of the population are presented in Table 1. PD-L1 status
of the tumor was available only for 30 (37.5%) patients and was
therefore not included in our statistical analysis.
The median time between completion of radiotherapy and ini-
tiation of immunotherapy was 368.5 days (range, 10–4864). Fif-
teen out of 80 (18.8%) patients presented with RRP.
Demographic, clinical and radiological characteristics of the 15
RRP patients are shown in Tables 2 and 3. The median time
between completion of radiotherapy and RRP was 450 days (range,
231–1859 days) and the median time between initiation of
immunotherapy and the occurrence of RRP was 61 days (range,
4–520 days). Twelve of 66 (18.2%) patients who received conven-
tionally fractionated radiotherapy presented radiation
pneumonitis > 6 months after irradiation, among whom 7 (10.6%)
patients developed radiation pneumonitis > 1 year after irradiation
(Fig. 2). One patient presented lung modifications 5 years after
radiotherapy completion. Of the 14 patients who received SBRT,
Table 2
Characteristics of the RRP patients.
Variables n = 15





CT characteristics, n (%)
Prior radiation fibrosis 11 (73)






Tumoral progression 8 (53)
Radiation pneumonitis 6 (40)
Infection 1 (7)
Median time between radiotherapy and RPP, d (IQR) 450 (498)
Median time between ICI and RRP, d (IQR) 61 (90)
1 Corresponding to the initial diagnosis made on CT at the time of realization of
the images. RRP, radiation recall pneumonitis; CTCAE, Common Terminology Cri-
teria for Adverse Events; IQR, interquartile range; ICI, immune checkpoint inhibitor.
Radiation recall pneumonitis and immune checkpoint inhibitors3 (21.4%) patients presented radiation pneumonitis > 1 year,
among whom 1 patient presented radiation pneumonitis 2 years
and 4 months after radiotherapy completion (Fig. 3). None of the
5 patients who received palliative radiotherapy presented with
RRP. If we look at the whole population regardless of the type of
irradiation received, 10 out of 80 (12.5%) patients presented with
radiation pneumonitis after 12 months.
The majority of cases of RRP were low grade, 2 of 15 (13.3 %)
patients presented a grade  3 pneumonitis and only 5 of 15
(33.3%) patients with RRP presented with symptoms. One patient
who presented RRP with grade 2 symptoms also presented with
synchronous signs of ICI-related pneumonitis on CT (nonspecific
interstitial pneumonia pattern) which could also have induced
symptoms.
PFS and OR medians were not significantly different between
patients with or without RRP (324 and 235 days, p = 0.99; 376
and 384 days, p = 0.84, respectively).Table 3
Individual characteristics of the 15 RRP patients.
Demographics RT Treatment Characteristics RRP Clinical Characteristics
Age Sex Smoking
history











78 M Yes Conventional 6.5 14.8 7 2
72 F Yes Conventional 14.1 26.8 11 1
78 M Yes SBRT 4.9 5.5 12 2
68 F Yes Conventional 15.7 26.3 10 1
69 M Yes Conventional 11.2 19.7 15 1
73 F No Conventional 4.8 8.9 40 27
78 M Yes Conventional 9.1 17.5 12 <1
68 M Yes SBRT 2.4 1.9 15 4
68 M Yes Conventional 16.4 27.1 17 2
64 M Yes Conventional 10.9 19.5 49 17
77 F Yes Conventional 12.6 22.5 14 4
63 M Yes SBRT 2.3 1 27 1
69 F Yes Conventional / / 61 <1
63 M Yes Conventional 12.7 23.7 8 3
55 M Yes Conventional 16.5 28.2 10 9
RRP, radiation recall pneumonitis; RT, radiotherapy; MLD, mean lung dose; ICI, immune
Adverse Events; GGO, ground glass opacity; SBRT, stereotactic body radiation therapy.
50Among the 15 patients with RRP, 11 (73.3%) patients demon-
strated signs of prior radiation-induced lung fibrosis on baseline
CT. RRP manifested on CT with ground glass opacity in 10
(66.7%) patients and with consolidation in 13 (86.7 %) patients. A
diffuse distribution of the lung abnormalities on CT was noted in
10 (66.7%) patients as opposed to patchy appearance in 5 (33.3)
patients (Fig. 4).
The reports that were generated at the time of realization of CT
correctly identified RRP in only 6 of 15 (40%) cases, RRP was mis-
taken for tumoral progression in 8 of 15 (53.3%) cases and with
infection in 1 of 15 (6.7 %) cases.
Table 1 shows the association between patient-, disease-, and
treatment-related variables and incidence of RRP. None of the fol-
lowing dosimetric factors was associated with RRP: the type of
irradiation (palliative, normally fractionated or SBRT) (p = .10),
the lung site irradiated (p = .50), the radiation dose (p = .58), the
dose per fraction (p = .86), the MLD (p = .84) and the V20 (p = .66).
The only variable that was significantly associated with RRP
was the presence of an ICI-related pneumonitis (p = .0021): 5 of
15 (33.3%) patients with RRP also presented with ICI-related pneu-
monitis, of whom 2 patients presented RRP and ICI-related pneu-
monitis concurrently and 3 patients presented initially with RRP
and later with ICI-related pneumonitis.Discussion
Our study describes the incidence of, and risk factors for, the
development of RRP in a population of previously irradiated
patients treated with PD-1/PD-L1 inhibitors for advanced lung can-
cer. To the best of our knowledge, no observational study has eval-
uated RRP in the setting of immunotherapy before. We observed in
our population an unexpectedly high incidence of RRP (18,8%),
occurring as late as 5 years after irradiation, without any identified
risk factor.
Radiation-induced lung injury is generally divided temporally
into two phases, an acute inflammatory phase called radiation
pneumonitis occurring within 6 months after radiotherapy com-
pletion, followed by a late or fibrotic phase developing after
6 months [17].
After conventionally fractionated radiotherapy, the first radio-











Yes 2 No Yes Diffuse RRP
Yes 1 Yes Yes Patchy RRP
No 1 No Yes Diffuse Progression
No 1 Yes Yes Patchy Progression
No 2 Yes Yes Diffuse RRP
Yes 1 Yes Yes Diffuse Progression
No 1 No Yes Diffuse Progression
Yes 3 No Yes Diffuse Progression
No 1 Yes Yes Patchy Progression
No 1 No Yes Diffuse RRP
No 1 Yes Yes Patchy RRP
Yes 2 Yes Yes Patchy Progression
No 1 Yes No Diffuse Infection
No 3 Yes Yes Diffuse Progression
No 1 Yes No Diffuse RRP
checkpoint inhibitor; IR, immune-related; CTCAE, Common Terminology Criteria for
Fig. 2. Axial chest CT images of a 73-year-old woman with a history of left breast cancer treated with radiotherapy 3.5 years ago who presents with a lung adenocarcinoma of
the right inferior lobe. The chest CT obtained 2 weeks before initiation of nivolumab in third line shows reticular opacities in the lung just behind the left breast corresponding
to radiation-induced lung fibrosis (a). The first follow-up CT 1 month after nivolumab initiation demonstrates the occurrence of a lung consolidation (white arrow) in the lung
area irradiated 3.5 years before (b). The follow-up CT obtained 8 months later demonstrates shrinkage of the consolidation and progression to fibrosis (c). Initial radiotherapy
plan with bolded orange and green lines corresponding respectively to the 10 Gy and 40 Gy isodose lines (d).
François Cousin, C. Desir, S. Ben Mustapha et al. Radiotherapy and Oncology 157 (2021) 47–55occur around 3 to 4 months [15,18–20]. They correspond patholog-
ically to an early inflammatory reaction of the lung secondary to
cellular damages and is characterized radiologically by ground-
glass opacities and/or consolidation visible on CT in the irradiation
field [16,21]. Concerning SBRT, lung modifications are also
expected to occur within 6 months after radiotherapy completion
but are typically delayed due to the higher dose per fraction, and
could appear up to one year after irradiation [15,22–24].
Most of the cellular damage related to radiation repairs over
time, but it is now recognized that changes in cellular function51and inflammation pathways can persist over time [25]. Among
these changes is the persistent damage to pulmonary stem cells.
Irradiation can cause stress-induced senescence of stem cells in
the lung parenchyma, making them unable to repair tissue damage
and capable of enhancing inflammatory reaction through the
secretion of cytokines and growth factors [26]. Long-term modifi-
cations in the T-cell population in irradiated lung, with an
increased number and alteration of the balance of T-cell subsets
due to distinct radiosensitivity, may also be implicated in
radiation-induced lung injury and latent inflammatory processes
Fig. 3. Axial chest CT images of a 63-year-old man presenting with a progressive squamous cell lung carcinoma of the right inferior lobe treated initially with stereotactic
body radiation therapy (510 Gy) and treated with nivolumab as a second line treatment initiated 25 months after SBRT completion. The chest CT obtained 2 weeks before
initiation of immunotherapy shows the tumor behind the right main bronchus (a). The first follow-up CT performed 1.5 months after initiation of immunotherapy shows the
occurrence of ground glass opacities associated with consolidation (white arrows) within the irradiation field 2 years and 4 months after completion of radiotherapy (b).
Follow-up CT demonstrates shrinkage of the consolidation and progression to fibrosis (c). Initial radiotherapy plan with bolded blue and yellow lines corresponding
respectively to the 5 Gy and 16 Gy isodose lines (d).
Radiation recall pneumonitis and immune checkpoint inhibitors[25,27,28]. Thus, lung parenchyma which has not reached the irra-
diation threshold to develop the chain reaction leading to pneu-
monitis, has yet experienced tissue injuries that sensitize it to
inflammatory reaction. This realize a latent pro-inflammatory
state, which can subsequently be reactivated, even years later.
Radiotherapy is now recognized as being an activator of several
key elements of the local immune response and interactions
between irradiation and immunotherapy are increasingly recog-
nized [29]. Several studies have focused on identifying the associ-
ation between the development of ICI-related pneumonitis and
previous chest radiotherapy. On the one hand, some studies have
shown no increase of all-grade pneumonitis in patients who have
previously received thoracic radiotherapy compared to patients
who have not [30,31]. On the other hand, in a secondary analysis52of the KEYNOTE-001 phase 1 trial, Shaverdian et al. noticed that
patients who previously received thoracic radiotherapy were more
likely to have any-grade pulmonary toxicity, especially pneumoni-
tis, suggesting the need for close toxicity monitoring in this subset
of patients [32]. The same observation was made by Antonia et al.
in the phase III PACIFIC trial in which they noticed a greater pro-
portion of pneumonitis in the group of patients receiving durval-
umab after chemoradiation for lung cancer compared to the
placebo group (33.9% versus 24.8%) [33]. These results suggest
the role of radiotherapy in priming the immune response and pro-
moting immune-mediated lung toxicity.
Interestingly, none of these studies has clearly differentiated
radiation pneumonitis from ICI-related pneumonitis. In our study,
we identified radiation pneumonitis as typical radiological changes
Fig. 4. Axial chest CT images of a 68-year-old man presenting with a small cell lung cancer of the left upper lobe treated initially with concomitant radio chemotherapy. After
progression, the patient was treated with immunotherapy (atezolimumab) in third line. The chest CT obtained 1 month before initiation of atezolimumab shows chronic
radiation-induced fibrotic lung changes in the left upper lobe (a). The first follow-up CT obtained 2 months after immunotherapy initiation shows the apparition of patchy and
nodular ground glass opacities (black arrow) in the irradiation field adjacent to the previous radiation-induced lung injury 1 year and 5 months after radiotherapy completion
which was confounded with tumour progression (b). Subsequent chest CT confirmed the evolution of pneumonitis to consolidation and fibrotic changes (c). Initial
radiotherapy plan with isodose lines with the bolded green line corresponding to the 36 Gy isodose line (d).
François Cousin, C. Desir, S. Ben Mustapha et al. Radiotherapy and Oncology 157 (2021) 47–55located within the irradiation field, as opposed to ICI-related pneu-
monitis which does not present with a specific pattern but is typ-
ically diffuse and rarely evolves into fibrotic changes [12,34–36].
However, the question of whether our observations correspond
to radiation pneumonitis or ICI-related pneumonitis occurring in
the irradiation field is relevant. Pozzessere et al., who looked at a
subset of 15 patients with ICI-related pneumonitis, noticed a pref-53erential location of pneumonitis in the irradiation fields if patients
had previously received radiotherapy. However, they ruled out
radiation pneumonitis when it occurred >6 months after radiother-
apy completion, despite their suggestion of a potential radiation
recall effect [37]. As a matter of fact, both mechanisms probably
overlap. In our population, we also noticed a significant association
between radiation pneumonitis and ICI-related pneumonitis, with
Radiation recall pneumonitis and immune checkpoint inhibitorsthe latter occurring either at the same time, or later, than RRP.
However, more studies are needed to gain a better understanding
of these crossed mechanisms.
Of particular interest is our finding of highly delayed radiation
pneumonitis in our population of patients treated with ICIs. Based
on this observation, we suggest that the usual definition of radia-
tion pneumonitis based on the onset time is no longer appropriate
in the immunotherapy setting, and a period of time >6 months
between radiotherapy and pneumonitis should not rule out the
diagnosis of radiation pneumonitis. The recognition of radiation
pneumonitis is of utmost importance in the context of oncological
follow-up, especially if it appears tardily after radiotherapy com-
pletion because a causal link is therefore more difficult to establish.
Our study also presents some limitations. First, it is a retrospec-
tive single institution analysis. Additional prospective studies with
larger sample sizes are required to confirm our observations. There
is no consensus definition of RRP in the literature, and we arbitrar-
ily defined RRP as changes appearing on CT > 6 months after con-
ventional radiotherapy and >1 year after SBRT, times that we
considered, based on data available in the literature, as unexpected
to develop radiation pneumonitis. However, we cannot assert that
all cases of RRP described here are truly related to ICIs. Moreover,
the RRP onset time we took into account in our study was the time
of the first CT on which lung changes were seen, and depended on
the frequency of the CT examination. Thus, this time could have
been overestimated in some cases. Additionally, RRP is an exclu-
sion diagnosis, this fact associated to the retrospective design of
our study could potentially have led to RRP misdiagnoses. Espe-
cially, as discussed above, it could be difficult to differentiate RRP
from localized ICI-related pneumonitis.
In conclusion, RRP is a delayed complication of radiotherapy
triggered by immunotherapy that can be easily misdiagnosed
and may occur at a higher rate than suggested in the literature.
In the future, it is expected that an increasing number of cancer
patients will be exposed to multiple treatment lines and treatment
associations, among which radiotherapy and ICIs, leading to higher
chances of developing combined toxicities, enhancing the impor-
tance of understanding and promptly recognizing them.Funding
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